Skip to Main Content

After the Obama administration unveiled a proposal to overhaul Medicare Part B four months ago, a large number of lawmakers quickly and very vocally opposed the effort. Now, a new analysis finds that drug makers, who are worried the plan will cut into their revenue, have given them considerably more financial support than lawmakers who have not raised objections.

Specifically, 310 lawmakers who either signed two letters opposing the overhaul or were critical of it received a total of more than $7.2 million from pharmaceutical and health products companies for their 2016 campaigns, according to the analysis by Public Citizen, the consumer advocacy group, which released its analysis on Monday. And the amount given to each representative averaged more than $23,300 (read the letters here and here).


By comparison, there were 124 rank-and-file lawmakers — 117 Democrats and seven Republicans — who did not sign either letter and received a combined total of nearly $1.6 million from the same industry for their 2016 campaigns. They averaged more than $12,700. The consumer group analyzed data from the Center for Responsive Politics and the Federal Election Commission.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.